201 related articles for article (PubMed ID: 33686514)
1. CHK1 kinase inhibition: identification of allosteric hits using MD simulations, pharmacophore modeling, docking and MM-PBSA calculations.
Al-Shar'i N; Musleh SS
Mol Divers; 2022 Apr; 26(2):903-921. PubMed ID: 33686514
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling, molecular docking and molecular dynamics simulations toward identifying lead compounds for Chk1.
Li Y; Peng J; Zhou Y; Li P; Li Y; Liu X; Siddique AN; Zhang L; Zuo Z
Comput Biol Chem; 2018 Oct; 76():53-60. PubMed ID: 29940486
[TBL] [Abstract][Full Text] [Related]
3. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
7. The design of TOPK inhibitors using structure-based pharmacophore modeling and molecular docking based on an MD-refined homology model.
Fakhouri LI; Al-Shar'i NA
Mol Divers; 2022 Oct; 26(5):2679-2702. PubMed ID: 35031933
[TBL] [Abstract][Full Text] [Related]
8. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
9. Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.
Lv M; Ma S; Tian Y; Zhang X; Lv W; Zhai H
Mol Biosyst; 2015 Jan; 11(1):275-86. PubMed ID: 25372494
[TBL] [Abstract][Full Text] [Related]
10. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents.
Kumar V; Khan S; Gupta P; Rastogi N; Mishra DP; Ahmed S; Siddiqi MI
J Comput Aided Mol Des; 2014 Dec; 28(12):1247-56. PubMed ID: 25312395
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach.
Giridhara Prema S; Chandrasekaran J; Kanekar S; George M; Prasad TSK; Raju R; Dagamajalu S; Balaya RDA
OMICS; 2024 Jan; 28(1):8-23. PubMed ID: 38190280
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
14. Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates for allosteric inhibition of EGFRT790M.
Çoban G
J Biomol Struct Dyn; 2024; 42(2):571-597. PubMed ID: 37029759
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling.
Bharatham K; Bharatham N; Kwon YJ; Lee KW
J Comput Aided Mol Des; 2008 Dec; 22(12):925-33. PubMed ID: 18685809
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel VEGFR2-TK inhibitors by phthalimide pharmacophore based virtual screening, molecular docking, MD simulation and DFT.
Matore BW; Roy PP; Singh J
J Biomol Struct Dyn; 2023; 41(22):13056-13077. PubMed ID: 36775656
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures.
Li Y; Kim DJ; Ma W; Lubet RA; Bode AM; Dong Z
J Chem Inf Model; 2011 Nov; 51(11):2904-14. PubMed ID: 21955044
[TBL] [Abstract][Full Text] [Related]
18. Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques.
Ramakrishnan C; Mary Thangakani A; Velmurugan D; Anantha Krishnan D; Sekijima M; Akiyama Y; Gromiha MM
J Biomol Struct Dyn; 2018 May; 36(6):1566-1576. PubMed ID: 28589758
[TBL] [Abstract][Full Text] [Related]
19. Computational simulation studies on the binding selectivity of Wee1 and Checkpoint kinase 1 by molecular dynamics simulation combined with free energy calculations.
Li Y; Liu X; Zhang S; Wang L; Zhang L; Zuo Z
J Biomol Struct Dyn; 2022 Feb; 40(3):1172-1181. PubMed ID: 33016857
[TBL] [Abstract][Full Text] [Related]
20. Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.
Chen XM; Lu T; Lu S; Li HF; Yuan HL; Ran T; Liu HC; Chen YD
J Mol Model; 2010 Jul; 16(7):1195-204. PubMed ID: 20020310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]